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Abstract Traditional cardiovascular risk factors have well-
known limitations for the accurate assessment of individual
cardiovascular risk. Unlike risk factor-based scores which rely
on probabilistic calculations derived from population-based stud-
ies, coronary artery calcium (CAC) scoring, and carotid ultra-
sound allow for the direct visualization and quantification of
subclinical atherosclerosis with the potential for a more accurate,
personalized risk assessment and treatment approach. Among
strategies used to guide preventive management, CAC scoring
has consistently and convincingly outperformed traditional risk
factors for the prediction of adverse cardiovascular events.More-
over, several studies have demonstrated the potential of CAC
testing to improve precision for the use of more intensive phar-
macologic therapies, such as aspirin and statins, in patients most
likely to derive benefit, as compared to atherosclerotic cardiovas-
cular disease risk calculators. By comparison to CAC, the role of
carotid ultrasound for the measurement of carotid intima-media
thickness (CIMT) remains less well-elucidated but may be sig-
nificantly improved with the inclusion of plaque screening and
novel three-dimensional measurements of plaque volume and
morphology. Despite significant evidence supporting the ability
of non-invasive atherosclerosis imaging (particularly CAC) to
guide preventive management, imaging remains an under-
utilized strategy among current guidelines and clinical practice.
Herein, we review evidence regarding CAC and carotid ultra-
sound for patient risk classification, with a comparison of these
techniques to currently advocated traditional risk factor-based
scores.
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Introduction
Iterative changes in primary prevention guidelines resulting in
increasingly intensive risk factor control have contributed to
significant reductions in the rates of atherosclerotic cardiovas-
cular disease (ASCVD)mortality. From 2001 to 2011, relative
rates of coronary heart disease and stroke mortality declined
by 30.8 and 35.1%, respectfully [1]. Despite these remarkable
reductions in cardiovascular mortality over the past several
decades, atherosclerotic cardiovascular diseases remain the
leading cause of death and preventable morbidity in the
USA and other industrialized nations [1]. It is estimated that
more than half of Americans will ultimately die of cardiovas-
cular diseases, and nearly half of all acute coronary events
occur in previously asymptomatic individuals [1]. Current
guidelines and ASCVD primary prevention paradigms are
based on the use of probabilistic risk scores that utilize a few
standard cardiovascular risk factors to estimate future ASCVD
risk [2••, 3••, 4••]. Widespread application of these popula-
tion-derived, risk factor-based scores is attractive as they are
simple, cheap, office-based and provide patients and providers
with quantitative risk estimates over both a 10-year and longer
term (30-year/lifetime) time horizon so to inform patient and
provider behavior. However, it is important to recognize that
there are numerous well-documented limitations to the wide-
spread, sole reliance on traditional risk factor-based scores for
the primary prevention of ASCVD inmany individuals. These
limitations, highlighted in part by controversy surrounding the
2013 American College of Cardiology/American Heart Asso-
ciation (ACC/AHA) Guideline on the Assessment of Cardio-
vascular Risk [2••], include concerns regarding imprecision in
ASCVD risk estimation when applying scores used to predict
population risk to an individual. For example, it is estimated
that current pooled cohort risk scores may broadly overesti-
mate ASCVD risk, potentially leading to large-scale overtreat-
ment in individuals unlikely to benefit from long-term treat-
ment with statins and aspirin [5–7], with potential for negative
cost and clinical consequences [8]. Further, without consider-
ing proven risk factors such as family history of premature
coronary heart disease, prior risk factor treatments (e.g., inten-
sity and duration of prior statin use), the variability in risk
factor measures (e.g., blood pressure), and the magnitude of
prior risk factor elevations (e.g., prior but not current
smoking), the use of “one-time” risk scores may significantly
underestimate risk in some individuals, potentially resulting in
under-treatment and less aggressive lifestyle modifications.
Importantly, current risk scores have not been prospectively
validated for their accuracy or ability to improve ASCVD
outcomes and also lack validation among a number of preva-
lent, contemporary ethnicities.
Interest in individualized risk prediction has grown based
on numerous studies involving diverse populations demon-
strating that atherosclerotic imaging for identification and
quantification of plaque burden more accurately identifies in-
dividual ASCVD risk as compared to risk scores and various
biomarkers and may, therefore, better guide the application
and intensity of preventative therapies [9–12]. Imaging has
the potential to integrate lifetime exposure to measured and
unmeasured (genetic, environmental) risk exposure and doc-
ument manifest atherosclerosis, the strongest risk factor for
future ASCVD events [13•]. As costs and radiation exposure
have declined and guidelines for the management of inciden-
tal findings have matured with regards to atherosclerosis im-
aging, its use for more personalized ASCVD risk assessment
has become increasingly attractive. Indeed, a central tenet in
ASCVD primary prevention is that the use and intensity of
preventative therapies should be matched to individual patient
risk based on data demonstrating that the most intensive treat-
ments are most effective when differentially applied to those
at greatest ASCVD risk.
Herein, we review the literature regarding two of the most
well-studied cardiovascular imaging techniques—coronary
artery calcium scanning (CAC) and carotid ultrasound—for
their use in the primary prevention of ASCVD events,
highlighting current guideline recommendations as well as
recommendations for implementation of these tests in patient
management given limitations of current ASCVD risk scores.
Limitations of Risk Factor-Based Scores for ASCVD
Prediction and Treatment Decision-Making
in Primary Prevention
The Framingham Risk Score (FRS) and similar risk factor-
based scores rely most heavily on chronologic age and gender
and are further refined through one-timemeasures of tradition-
al modifiable cardiovascular risk factors, such as smoking
status, blood pressure, cholesterol (total cholesterol and
high-density lipoprotein cholesterol), and diabetic status.
However, while the FRS is useful, it has been shown to only
modestly predict incident coronary heart disease (CHD)
events (coronary death and myocardial infarction (MI)), with
a C-statistic of approximately 0.70 [6, 14].
Recently, the authors of the 2013 ACC/AHA guideline
on the assessment of cardiovascular risk and the 2013
ACC/AHA guideline on the treatment of cholesterol de-
rived a new risk calculator (pooled cohort risk equations)
designed to estimate risk for both CHD and stroke
(ASCVD) in white and black patients, while simultaneous-
ly reducing the risk threshold for the use of statin medi-
cations in patients without manifest ASCVD. In addition,
the authors advocated for the use of longer-term risk cal-
culators for the assessment of lifetime cardiovascular risk
to potentially guide treatment decision-making in patients
where statin medication were not clearly recommended by
the 10-year ACC/AHA ASCVD (pooled cohort) equation.
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As stated above, the pooled cohort equations were recom-
mended despite no prospective validation of their accuracy
in contemporary populations and no studies documenting
improved outcomes with their implementation. Moreover,
several analyses in more contemporary populations than
the derivation studies suggest that the pooled cohort equa-
tion may significantly overestimate ASCVD risk and the
subsequent number of patients who would be likely to
benefit from life-long statin therapy [5–7]. For example,
comparison of the 2013 ACC/AHA ASCVD risk score,
Framingham-based risk scores, and the Reynolds Risk
Score (RRS) for the prediction of ASCVD events in
4967 Multi-Ethnic Study of Atherosclerosis (MESA) sub-
jects followed over a median of 10.2 years demonstrated
gross overestimation of risk by 37–154 % in men and 8–
67 % in women, regardless of prior statin or aspirin treat-
ment or subsequent coronary interventions [6]. In that
study, among men with a 10-year ACC/AHA ASCVD risk
score of 7.5–10 %, the observed event rate was only 3 %.
Within this analysis, 49 % of subjects would have been
stratified to moderate-high intensity statins, among which
41 % had a CAC (Agatston) score of 0, a group demon-
strated repeatedly to have an exceedingly low event rate
(5.2 events per 1000 patient years in this 10-year analy-
sis). Similarly, potential under-treatment also occurred. For
example, 5 % of patients not considered eligible for statin
therapy had a CAC score >100, a group with high
ASCVD risk. Overestimation of risk to variable degrees
was demonstrated in several other modern primary preven-
tion cohorts, demonstrating that the 2013 ACC/AHA
ASCVD risk calculator only provides modest discrimina-
tory predictive value (C-statistic ~0.7), particularly in
white subjects and those previously treated with statins
[5, 14, 15].
Not surprisingly, risk scores calculated at a single point
in time may be inherently limited due to their inability to
account for genetic influences, variability in measured risk
factors (e.g., blood pressure) and prior, untreated risk factor
severity and exposure duration. For example, prior smoking
exposure is not considered in the current ACC/AHA
ASCVD equation (only current smoking), ignoring poten-
tially decades of exposure to one of the strongest ASCVD
risk factors. Similarly, family history is also not considered
in the 2013 ACC/AHA ASCVD risk score, with the clini-
cal assessment of family history significantly downgraded
as compared to prior risk assessment/primary prevention
guidelines (from class I to IIb) [2••, 16]. Within the MESA
study and other primary prevention cohorts, family history
of premature CHD has been shown to be among the most
powerful risk factors for the prediction of subsequent ad-
verse cardiovascular events and is also strongly associated
with more advanced subclinical atherosclerosis [17–19,
20••].
The Evidence for Atherosclerosis Imaging
to Improve ASCVD Risk Assessment and Primary
Prevention
Coronary Artery Calcium Scoring
Coronary artery calcium scanning is a rapid, non-contrast
computed tomography (CT) of the heart used to identify cal-
cification—defined as an area of ≥3 adjacent pixels (or
1 mm2) of at least 130 Hounsfield units—within epicardial
coronary arteries. It is simple, can be performed in any patient
with a single breath-hold and at very low-radiation exposure
(≤1 mSv), comparable to radiation exposure associated with
screening mammography [21, 22]. Coronary artery calcifica-
tion is most commonly quantified using the Agatston method
and is highly reproducible, resulting in the ability to categorize
absolute scores as 0 (no CAC), 1–10 (minimal CAC), 11–100
(mild), 101–400 (moderate), >400 (severe), and >1000 (very
severe). In addition to absolute scores, coronary atherosclero-
sis severity, as measured by CAC scoring, can be compared to
asymptomatic subjects of the same age, gender, and ethnicity
using established databases (e.g., MESA), resulting in calcu-
lation of an individual CAC percentile score, with both abso-
lute and percentile scores used for cardiovascular risk refine-
ment and medical decision-making (Figs. 1 and 2) [23].
Prognostic Accuracy of Coronary ArteryCalcium Scoring
Coronary artery calcium scoring has been repeatedly demon-
strated to be the most robust predictor of coronary events in
asymptomatic patients, particularly in patients estimated to be
at intermediate risk based on risk factor scores. Without ex-
ception, every large-scale study performed to date has shown
CAC to be superior to risk factor scores, with CAC resulting
Fig. 1 Kaplan-Meier curve for coronary heart disease events according
to the coronary artery percentile score in theMESA (multi-ethnic study of
atherosclerosis). AC coronary artery calcium, CHD coronary heart
disease. Reproduced with permission from [23]
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in significant reclassification of patients (Table 1). The MESA
study, representing one of the most comprehensive prospec-
tive studies of CAC to date, is a large-scale (n=6814) National
Heart, Lung, and Blood Institute-sponsored study of CAC
involving asymptomatic adult subjects (mean age 62 years)
comprising four different ethnicities from the USA [10]. Initial
study analysis performed at a mean of 3.8 years of follow-up
for incident CHD confirmed earlier studies regarding the su-
periority of CAC over standard risk scores. Specifically, com-
pared with patients that had a CAC score of 0, patients with
CAC of 1–100 had a risk-adjusted hazard ratio of 3.61 for any
cardiac event. For higher CAC scores, the hazards ratio in-
creased incrementally to 7.73 and 9.67 for CAC scores of
101–300 and >300, respectively. Compared to standard risk
variables, the addition of CAC markedly improved the accu-
racy of CHD event prediction, significantly increasing the area
under the receiver-operating characteristic curve from 0.77 to
0.82 (p<0.001). Further analysis demonstrated that, compared
to the FRS, CAC resulted in significant net reclassification of
individuals tomore accurate risk categories [24]. For example,
within MESA, the overall net reclassification index (NRI) of
CAC over 5 years of follow-up was 25 % (meaning, 25 % of
subjects were more accurately classified to a different risk
category), with NRI values of 11.6, 54.4, and 35.0 % for
FRS categories of 0–6 % (low risk), 6–20 % (low-intermedi-
ate risk), and >20 % (high risk), respectively. These findings
were confirmed in several other large-scale prospective
studies, demonstrating virtually identical NRI values (NRI
19–22 % overall), with NRI values of >50 % for patients at
intermediate risk by the FRS [25, 26]. Follow-up of MESA
participants extending to beyond 10 years (and up to 14 years)
has confirmed the long-term prognostic value of CAC scoring
[27–29].
One of the criticisms of CAC scoring raised by the authors
of the 2013 ACC/AHA risk assessment guidelines is the focus
on CHD outcomes by most CAC studies, with little data re-
garding the prognostic value of CAC for the combined out-
come of ASCVD; the endpoint estimated by the current ACC/
AHA ASCVD calculator. Given the impressive net reclassifi-
cation demonstrated by CAC scoring and the population clin-
ical and cost burden of CHD as a critical part of ASCVD, this
criticism appeared to be shortsighted, particularly given limi-
tations of risk scores. Investigators from the MESA study
recently demonstrated that CAC scoring was also superior to
standard cardiovascular and stroke risk factors for the predic-
tion of stroke and overall ASCVD [6, 30], similar to findings
from the Heinz Nixdorf Recall Study [31]. In addition, CAC
testing appears to be superior to long-term risk scores (lifetime
risk scores) for the prediction of CHD events [32].
The use of biomarkers, such as high-sensitivity C-reactive
protein (hs-CRP), has also been explored as a potential ap-
proach to further improve risk factor-based approaches to
ASCVD primary prevention, as with the Reynold’s Risk
Score [14, 33]. Current risk assessment guidelines discuss
hs-CRP as a possible tool in select patients [2••]. However,
numerous studies comparing CAC to hs-CRP have repeatedly
demonstrated it to be inferior to CAC for cardiovascular event
prediction, noting that it poorly correlates with coronary ath-
erosclerotic disease burden and demonstrates significant intra-
individual variability on repeat testing, limiting its usefulness
and attractiveness as a one-time biomarker utilized to base
life-long treatment and risk assessments [20••, 34, 35•, 36,
37]. As one example, among 706 individuals in MESA,
69 % with a hs-CRP >3.0 mg/L (high risk category) were
subsequently noted to have a discordant hs-CRP level in a
low-risk category on repeat testing, with hs-CRP demonstrat-
ing greater intra-individual variability than standard cholester-
ol levels utilized for risk scoring [38]. The MESA investiga-
tors attempted to assess the role of hs-CRP using the Justifi-
cation for the Use of Statin in Prevention: An Intervention
Trial Evaluating Rosuvastatin (JUPITER) trial inclusion
criteria (hs-CRP >2 and low-density lipoprotein <130 mg/dl)
and matched them to MESA subjects with hs-CRP <2 [35•].
They found no effect of hs-CRP on outcomes and no relation-
ship of hs-CRP to CAC (Fig. 3). Additionally, based on ex-
pected event rate reduction from statins, estimated number
needed to treat (NNT) for rosuvastatin was 549, 94, and 24
for CAC score of 0, 1–100, and >100, respectively. Studies
assessing the use of multiple biomarkers added to standard
risk factor-based scores have similarly shown inferior
Fig. 2 Rates of incident coronary heart disease per 1000 person years at
risk by joint categories of the absolute coronary artery calcium group and
age, sex, and race/ethnicity-specific percentiles. The rates of incident
CHD per 1000 person years at risk by joint categories of the absolute
CAC group and age-, sex-, and race/ethnicity-specific percentiles are
displayed. Within a particular level of age, sex, and race/ethnicity-
specific percentiles, there remains a clear trend of increasing risk across
levels of the absolute CAC groups. In contrast, once the absolute CAC
category is fixed, there is no increasing trend across levels of age, sex, and
race/ethnicity-specific categories. CAC coronary artery calcium, CHD
coronary heart disease. Reproduced with permission from [23]
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performance as compared to direct measurement of coronary
atherosclerotic burden using CAC [39].
Power of Zero and Impact of CAC on Cost, Treatment,
and Outcomes
One of the most consistent findings across all studies of CAC is
the impressively low 10-year cardiovascular risk (approximately
1%) observed in subjects with CAC=0, regardless of risk factor
status [40, 41]. Given concerns about overestimation ofASCVD
risk and subsequent overtreatment, calcium scoring provides the
potential to focus preventative treatments more appropriately,
while avoiding unnecessary treatment in patients at very low
ASCVD risk (CAC=0). While CAC testing is generally cheap
to perform (≤$100), many have raised concerns about increased
costs induced from the utilization of CAC scoring due to in-
creased subsequent downstream cardiovascular testing [42]. In
the Early Identification of Subclinical Atherosclerosis by Non-
invasive Imaging Research (EISNER) study, CAC testing was
compared to usual care in asymptomatic adults without baseline
ASCVD for the primary outcome of change in calculated car-
diovascular risk [43, 44]. In an EISNER cohort of 1381 subjects,
additional cardiovascular testing was differentially performed
according to CAC severity: infrequent in patients with minimal
or no CAC (CAC<10) but more frequently among participants
with CAC scores ≥400. Similarly, the rate of invasive coronary
angiography and coronary revascularizations at 1-year were
higher in those with severely elevated CAC scores (19 % of
subjects with a CAC score ≥1000). However, the performance
of CAC testing did not significantly increase overall healthcare
costs as the absence of CAC was associated with significantly
lower rates of subsequent cardiovascular testing and costs. CAC
scoring was also associated with overall significant improve-
ments in several cardiovascular risk factors (blood pressure,
low-density lipoprotein cholesterol, and waist circumference),
with findings similar to other studies demonstrating increased
adherence to primary prevention medications among patients
with prevalent CAC [45]. In addition, an analysis of the MESA
demonstrated the importance of appropriate patient selection
and risk of overtreatment in the application of primary preven-
tative therapies. For example, among subjects with CAC=0, the
use of aspirin was estimated to result in net harm, while the
application of aspirin for primary prevention in patients with
Table 1 Prognostic power of coronary artery calcium in asymptomatic patients
First author
[Ref. #]
N Mean
age
(years)
Follow-up
(years)
Agatston calcium
score
cutoff
Comparator group for
relative risk
calculation
Relative
risk ratio
Arad et al. [9] 1173 53 3.6 >160 <160 20.2
Wong et al. [63] 926 54 3.3 Top quartile (>270) First quartile 8.8
Greenland et al. [16] 1312 66 7.0 >300 No CAC 3.9
Shaw et al. [46•] 10,377 53 5 ≥400 ≤10 8.4
Arad et al. [34] 5585 59 4.3 ≥100 <100 10.7
Taylor et al. [12] 2000 40–50 3.0 >44 0 11.8
Vliegenthart et al. [64] 1795 71 3.3 >1000 <100 8.3
400–1000 <100 4.6
Budoff et al. [46•] 25,503 56 6.8 >400 0 9.2
Lakoski et al. [65] 3601 45–84 3.75 >0 0 6.5
Becker et al. [66] 1726 57.7 3.4 >400 0 6.8 men
7.9 women
Detrano et al. [10] 6814 62.2 3.8 >300 0 14.1
Erbel et al. [26] 4487 45–75 5 >75th percentile <25th percentile 11.1 men
3.2 women
Fig. 3 Relationship of high-sensitivity C-reactive protein to coronary
artery calcium score and coronary heart disease event rates in MESA.
MESA multi-ethnic study of atherosclerosis. Reproduced with
permission from [35•]
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CAC ≥100 (at higher risk) was demonstrated to be effective in a
net clinical benefit analysis [8].
Unfortunately, there are no prospective, randomized out-
comes trials assessing the impact of CAC testing on long-term
outcomes. St. Francis Heart Study investigators randomized
1005 with severely elevated CAC (>80th percentile) asymp-
tomatic subjects to atorvastatin 20 mg daily or placebo and
reported a significant reduction (15.0 vs. 8.7 %; p=0.046) in
major adverse cardiovascular events (inclusive of coronary
and peripheral revascularization) over 4.3 years of follow-up
among those with a baseline CAC score >400 treated with
atorvastatin. Unfortunately, further large-scale studies have
not yet been performed, likely due to cost concerns related
to the expected size and duration of such a study [46•].
The Evidence for Atherosclerosis Imaging
to Improve ASCVD Risk Assessment and Primary
Prevention
Carotid Intima-Media Thickness and Plaque Screening
Ultrasonography for the measurement of carotid artery intima-
media thickness (CIMT) and carotid plaque in asymptomatic
screening populations has been extensively studied and well-
described. Compared to CAC, the use of ultrasonography for
the detection of subclinical atherosclerosis for primary
ASCVD risk prevention purposes is attractive as it requires
no ionizing radiation, may result in few incidental findings, is
highly reproducible, and can typically be done in an office
setting with appropriately trained personnel. Furthermore, ca-
rotid ultrasonography can be performed using equipment and
software often already available to patients and clinicians.
Current measurement techniques, aided by modern high-
frequency ultrasound equipment and semi-automatic mea-
surement software, are well delineated in current guideline
statements and have been shown to be highly reproducible
among trained sonographers [47, 48]. While performance of
carotid ultrasonography is not the focus of this review, the
American Society of Echocardiography (ASE) recommends
that CIMT be measured using ultrasound images from the
distal 1 cm of the far wall of each common carotid artery
(CCA), as measurements involving the near wall are often
suboptimal, but also that CIMT measurement be supplement-
ed with a carotid plaque-screening scan of the full extracranial
carotid arterial system [47]. Specifically, this plaque screen
involves obtaining circumferential scans of the CCA, carotid
bulb, and internal and external carotid arteries. The actual
CIMT measurement is obtained by tracing the blood-intima
and media-adventitia boundaries along a 1-cm length of the
CCA far wall using a leading-edge to leading-edge technique.
Automated border detection programs can be used to reduce
measurement variabil i ty when performing CIMT
measurements.
Carotid plaque is defined by the ASE as the presence of
focal wall thickening that is at least 50 % greater than that of
the surrounding vessel wall or as a focal region with CIMT
>1.5 mm that protrudes into the lumen that is distinct from the
adjacent boundary. Plaque measurements (e.g., volume or
morphology) further characterized outside of either the pres-
ence or absence of plaque has not been well studied and thus
far has not been incorporated in imaging interpretation. The
European Society of Cardiology (ESC) definition of carotid
plaque differs slightly. The ESC defines CIMTof >0.9 mm as
abnormal and plaque as any focal structure of the inner vessel
wall measuring at least 0.5 mm or greater or any IMT mea-
surement greater than or equal to 1.5 mm [3••].
Prognostic Accuracy of CIMTand Plaque by Carotid
Ultrasound
The major studies assessing the prognostic value of CIMTare
summarized in Table 2. It is important to note when consider-
ing the evidence base that there is significant heterogeneity
across studies with regards to the site of CIMT and plaque
assessments. For example, many studies included both near
and far wall measurements in their data sets and not all includ-
ed plaque screening. With inconsistency in the acquisition of
CIMT values, so too is the inconsistency in reported values.
Measurements are usually reported as an average of all mea-
surements, mean maximum (average of the maximum value
for all segments), or individual maximum values from any
segment. Carotid plaque definitions also varied, with
reporting as present or present and characterized by risk
(low, intermediate, or high risk plaque) without further spec-
ification. Some studies include plaque measurements as part
of CIMT, consistent with ASE recommendations, although
this was not uniform. As such, attempts to derive consensus
on the use of CIMT for risk prediction have suffered from
significant heterogeneity between studies.
Notwithstanding the heterogeneity in CIMTmeasurements
across studies, viewed in its entirety and considering the best
available evidence, it appears that increasing CIMT is associ-
ated with an independent increase in ASCVD events. Howev-
er, the ability of CIMT to predict adverse events as compared
to risk factors, without consideration of carotid plaque, is less
robust. For example, the NRI using CIMT alone from current
studies (Table 2) has been shown to be minimal, ranging from
0 to 12 %. Notwithstanding issues with study population and
measurement heterogeneity, it is important to note that the
measurement of CIMT and plaque may represent variations
of atherosclerotic pathophysiology. For example, while CIMT
represents the thickness of the intima-media, an area that in-
creases both as a factor of aging and smooth muscle hypertro-
phy, plaque is specific for overt atherosclerosis, a process
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resulting from the deposition of foam cells, smooth muscle
cells, macrophages, lipid core, and a fibrous cap [47, 49•].
Hence, subjects with overt plaque may represent a distinctly
higher risk population.
In the Atherosclerosis Risk in Communities study (ARIC)
of 13,145 health subjects between 45 and 64 years of age at
the time of baseline carotid ultrasonography, the best model to
predict incident cardiovascular events (during mean follow-up
of 15.2 years) included traditional risk factors, CIMT, and
plaque (Fig. 4) [11]. The NRI for CIMTwas 9.9 %; however,
the addition of plaque to any level of CIMT (<25th percentile,
25–75th percentile or >75th percentile) significantly improved
risk prediction in men and particularly among women. A
meta-analysis of 11 population-based studies (n=54,336) con-
firmed the ARIC findings, concluding that carotid plaque,
when compared to CIMT alone (inclusive of various sites of
measurement), had significantly higher diagnostic accuracy
for incident myocardial infarction [50]. Similarly, meta-
analyses limited to only CIMT versus those including plaque,
despite several common authors, have reached opposite con-
clusions regarding the role of carotid ultrasonography for the
prediction of ASCVD events. Across studies incorporating
plaque, the NRI of carotid ultrasonography is ~8–11 %, with
more robust results for CIMT and carotid plaque among stud-
ies utilizing patient level data (the most accurate method for
performing a meta-analysis) [51, 52].
The improvement in risk prediction with inclusion of ca-
rotid plaque may not be surprising. In addition to potential
differences in pathology between CIMT and plaque, overt
plaque tends to form at the carotid bulb and internal carotid
artery, areas often excluded from CIMT measurements.
Hence, the exclusion of plaque from many CIMT studies
may explain the less robust predictive value of CIMT alone.
More recently, studies have attempted to further refine plaque
assessment, moving from binary plaque classification (present
vs. absent) to more quantitative and qualitative descriptions
using 3-dimensional imaging techniques [53, 54]. It remains
to be seen whether the assessment of carotid plaque area, vol-
ume, and plaque characteristics assessed using modern 3-
dimensional measurements, such as surface irregularity,
echolucency, and plaque texture, can further improve risk strat-
ification. Interestingly, 3-dimensional assessment of plaque vol-
ume does appear to correlate more strongly with CAC scoring
than CIMT, highlighting the promise of this technology [54].
CAC Versus CIMTand Carotid Plaque
Several observations can be made from the studies that have
compared the prognostic performance of CAC and carotid
ultrasonography. First, CAC appears to be significantly more
powerful than CIMT for the prediction of CHD events. Spe-
cifically, the NRI for CAC is consistently >20 % for CHD
events and reaches >50 % among intermediate risk individ-
uals, as compared to NRI values typically <10 % for carotid
plaque measures. In the MESA study, CAC was superior to
CIMT (without plaque assessment), hs-CRP, family history,
and other novel risk markers for incident CHD event predic-
tion [20••] and was superior to CIMT (without plaque
assessed) for stroke prediction in the Heinz Nixdorf Recall
study [55]. However, CIMT measurements may be compara-
ble to CAC for the prediction of ASCVD events in elderly
Fig. 4 Adjusted coronary heart disease incidence rate per 1000 person
years adjusted by CIMT categories with and without plaque. For every
carotid intima-media thickness (CIMT) category (i.e., <25th percentile,
25th to 75th percentile, and >75th percentile), for the overall group (green
bars), men (yellow bars), or women (orange bars), having carotid artery
plaque is associated with a higher incidence of coronary heart disease.
Reproduced with permission from [11]
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subjects [56, 57]. Finally, carotid ultrasonography may be
more sensitive for the detection of early, subclinical athero-
sclerosis, particularly in younger patients without CAC [58].
The prognostic implications of this finding remain to be elu-
cidated, particularly given the known excellent prognosis in
patients with CAC=0.
Guideline and Appropriate Use Recommendations
for CAC and Carotid Ultrasound
Coronary Artery Calcium Scoring
With few exceptions, CAC testing is often recommended for
use in asymptomatic patients at intermediate risk for CHD by
standard risk assessment (Table 3). The 2013 ACC/AHA
guidelines on cardiovascular risk assessment and cholesterol
treatment suggest that CAC scoring may be reasonable (IIb
recommendation) for further risk assessment in patients with a
5 to 7.5 % 10-year ASCVD risk [2••, 4••]. Within this low-
intermediate risk group, the guideline writers suggest a
threshold (based on expert opinion) of 300 Agatston units
or 75th percentile (for age, sex, and ethnicity), above
which risk assessment should be revised upward, poten-
tially influencing decision to initiate statin treatment. Of
note, this is a significant change from the 2010 guidelines
which considered CAC testing and CIMT testing as rea-
sonable to perform (IIa recommendation) in patients at
intermediate risk (10–20 % FRS) [16]. The 2012 practice
guidelines from the European Society of Cardiology
Table 3 Recommendations for CAC testing and carotid ultrasound
CAC coronary artery calcium, CAD coronary artery disease, CHD coronary heart disease, CIMT carotid intima-media thickness, FRS Framingham Risk
Score, SIHD stable ischemic heart disease
a Endorsed by ACCF/SCCT/ACR/AHA/ASE/ASNC/NASCI/SCAI/SCMR
bEndorsed by ACCF/AHA/ACP/AATS/PCNA/SCAI/STS
c ESC guidelines utilize the Systematic Coronary Risk Evaluation Project (SCORE calculator), where moderate risk is ≥1 and <5 % risk of fatal CVD at
10 years
d CCS guidelines state CAC superior to CIMT, and argues to consider CAC among secondary tests, but qualifies need for further data before CAC can be
widely advocated
e For whom further risk assessment is indicated (e.g., strong family history of premature CAD, abdominal obesity, South Asian ancestry, or impaired
glucose tolerance)
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support a similar approach, recommending that CAC should
be considered in asymptomatic patients at moderate risk via
traditional risk factor assessment (10-year CVD risk between
1 and 5 % by the SCORE calculator) [3••]. Similarly, the
Canadian Cardiovascular Society recommends consideration
of secondary non-invasive ASCVD testing (including CAC
score) for intermediate-risk patients and further specifies that
a statin should be started when CAC exceeds 100 [59]. Of
note, current appropriate use criteria consider CAC testing
appropriate in a number of patient cohorts. For example, the
2010 ACC/AHA appropriate use criteria for cardiac CT con-
sider CAC appropriate in patients at intermediate CHD risk
(10–20 % by FRS), and those at low risk (<10 % FRS) with a
family history of premature CHD [60]. Similarly, the 2014
American College of Radiology (ACR) Appropriateness
Criteria for CAD recommending CAC as a complementary
risk stratification tool that is “usually appropriate” in interme-
diate risk patients and “may be appropriate” in low-risk pa-
tients with a family history of early CHD [61]. By comparison
to older recommendations, the US Preventive Services Task
Force found insufficient evidence in 2009 to recommend
CAC testing in asymptomatic patients with no known history
of CVD, citing the need for additional data on utility and cost-
effectiveness (even in patients at intermediate risk by tradi-
tional risk assessment methods) [62].
Carotid Intima-Media Thickness
By comparison to CAC testing, recommendations for carotid
intima-media thickness (CIMT) use vary considerably
(Table 3). The 2013 ACC/AHA guidelines state that CIMT
should not be routinely performed (Class III; no benefit), re-
gardless of initial risk stratification by traditional methods
[2••]. Of note, carotid plaque screening was not discussed.
In contrast, the 2012 European Society of Cardiology
and 2010 ACC/AHA guidelines recommend CIMT use
(Class IIa; reasonable) for further evaluation of moderate
or intermediate risk patients [3••, 59]. Despite variable
recommendations for CIMT use, the guidelines agree that
when CIMT is performed, it should be performed by an
experienced operator to ensure a consistent approach and
meaningful interpretation of findings across centers. Simi-
lar to CAC, CIMT was not endorsed by the USPTF citing
the need for additional outcomes studies [62].
Conclusions
Despite a significant decline in the rate of death from ASCVD
over the past several decades, cardiovascular diseases remain
the most common cause of morbidity and mortality in most
countries. While efforts to refine traditional risk factor-based
risk scores to more accurately predict ASCVD among several
ethnicities were admirable, we feel that sole reliance on cur-
rent ASCVD risk scores performed at a single point in time
may be a fundamentally suboptimal, particularly when mak-
ing life-long treatment decision in asymptomatic patients.
Non-invasive imaging for the detection and quantification of
subclinical atherosclerosis, particularly utilizing low-radiation
CAC testing, has been definitely proven to be superior to risk
factors-based scores for prognostic accuracy, especially in pa-
tients at intermediate risk according to risk scores or those
with a family history of early cardiovascular disease. As data
continues tomature for both CAC and carotid plaque imaging,
public acceptance of the status quo with regards to the limita-
tions of current risk factor-based prevention strategies, com-
bined with physician awareness, may lead to increased appro-
priate use of imaging to more effectively prevent ASCVD.
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